IoM drug safety committee meeting
Executive Summary
IoM Committee on the Assessment of the U.S. Drug Safety System will hold its second meeting July 19-20 at the National Academy of Sciences Building in Washington, D.C. The meeting will be open to the public from 3 p.m.-6 p.m. the first day and 1 p.m.-5:30 p.m. the second day. The IoM panel held its first meeting on June 8 (1"The Pink Sheet" June 13, 2005, p. 6)...
You may also be interested in...
IoM Drug Safety Review Should Reach Beyond FDA, Agency’s Woodcock Says
The scope of the Institute of Medicine's assessment of the U.S. drug safety system must extend beyond an evaluation of FDA's capabilities, FDA Acting Deputy Commissioner for Operations Janet Woodcock said June 8
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.